Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lombard gets all-clear to test AAA Aorfix graft in US clinical trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given Lombard Medical Technologies the go-ahead to begin a clinical trial of its Aorfix endovascular stent graft for treating abdominal aortic aneurysms (AAAs). The first part of the trial, which the UK firm said would begin this quarter, will be conducted at 20 centres and will involve over 250 patients with AAAs and with aortic neck angulations of 60degrees or less being treated with Aorfix. These patients will be compared with a control group of 110 subjects unsuitable for endovascular graft therapy, who will receive conventional open surgery. Recruitment is expected to take 12-15 months and patients will be followed up for a year. Aorfix is currently being commercialised in Europe, said the Didcot, Oxfordshire-based company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel